125 related articles for article (PubMed ID: 37862797)
1. Response to programmed cell death protein 1 antibody in patients with Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.
He WZ; Huang YH; Hu WM; Wang F; Xu YX; Yi JH; Xue J; Yang YZ; Chao XY; Lin HB; Guo GF; Yun JP; Xia LP
Eur J Cancer; 2023 Nov; 194():113337. PubMed ID: 37862797
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.
Huang YH; Zhang CZ; Huang QS; Yeong J; Wang F; Yang X; He YF; Zhang XL; Zhang H; Chen SL; Zheng YL; Deng R; Lin CS; Yang MM; Li Y; Jiang C; Kin-Wah Lee T; Ma S; Zeng MS; Yun JP
J Hepatol; 2021 Apr; 74(4):838-849. PubMed ID: 33212090
[TBL] [Abstract][Full Text] [Related]
3. PD-1 blockade and radiotherapy combination for advanced Epstein-Barr virus-associated intrahepatic cholangiocarcinoma: a case report and literature review.
Liao CX; Deng CS; Liang X; Yang JC; Chen ZZ; Lin XY; Lin CF; Chen S; Wu SS
Front Immunol; 2023; 14():1239168. PubMed ID: 37753076
[TBL] [Abstract][Full Text] [Related]
4. The immune microenvironment features and response to immunotherapy in EBV-associated lymphoepithelioma-like cholangiocarcinoma.
Chiang NJ; Hou YC; Tan KT; Tsai HW; Lin YJ; Yeh YC; Chen LT; Hou YF; Chen MH; Shan YS
Hepatol Int; 2022 Oct; 16(5):1137-1149. PubMed ID: 35780451
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathological features of a rare cancer: Intrahepatic lymphoepithelioma-like cholangiocarcinoma with Epstein-Barr virus infection.
Zheng L; Zhou N; Yang X; Wei Y; Yi C; Gou H
Clin Res Hepatol Gastroenterol; 2023 Dec; 47(10):102244. PubMed ID: 37944749
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus-associated intrahepatic cholangiocarcinoma bearing an intense lymphoplasmacytic infiltration.
Xiao P; Shi H; Zhang H; Meng F; Peng J; Ke Z; Wang K; Liu Y; Han A
J Clin Pathol; 2012 Jun; 65(6):570-3. PubMed ID: 22267965
[No Abstract] [Full Text] [Related]
7. Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China.
Shi C; Li Y; Yang C; Qiao L; Tang L; Zheng Y; Chen X; Qian Y; Yang J; Wu D; Xie F
Front Immunol; 2022; 13():946861. PubMed ID: 35967452
[TBL] [Abstract][Full Text] [Related]
8. Absence of Epstein-Barr virus (EBV) in intrahepatic cholangiocarcinoma confirmed by lack of EBV-coded nuclear RNA and latent membrane protein-1.
Ozaki S; Harada K; Watanabe K; Furubo S; Tsui WM; Nakanuma Y
Histopathology; 2000 Jan; 36(1):50-3. PubMed ID: 10632752
[TBL] [Abstract][Full Text] [Related]
9. Real-world outcomes of patients with advanced intrahepatic cholangiocarcinoma treated with programmed cell death protein-1-targeted immunotherapy.
Deng M; Li S; Wang Q; Zhao R; Zou J; Lin W; Mei J; Wei W; Guo R
Ann Med; 2022 Dec; 54(1):803-811. PubMed ID: 35272564
[TBL] [Abstract][Full Text] [Related]
10. Prognostic roles of leptin-signaling proteins, PD-L1, and tumor-infiltrating lymphocytes in surgically-resected biliary tract cancers.
Byeon SJ; Chang MS; Cho HJ; Park JH; Kim KH; Park JH; Choi IS; Kim W; Han DS; Ahn HS; Heo SC
J Surg Oncol; 2023 Mar; 127(4):587-597. PubMed ID: 36367404
[TBL] [Abstract][Full Text] [Related]
11. Epstein
Peng L; Peng X; Duan S; Zhang Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2024 Feb; 49(2):319-330. PubMed ID: 38755729
[TBL] [Abstract][Full Text] [Related]
12. [Epstein-Barr virus associated lymphoepithelioma-like cholangiocarcinoma: a clinicopathological analysis of three cases].
Du MZ; Guo LC; Huang S; Guo X; Zhu BY
Zhonghua Bing Li Xue Za Zhi; 2023 Aug; 52(8):841-843. PubMed ID: 37527991
[No Abstract] [Full Text] [Related]
13. Lymphoepithelioma-like cholangiocarcinoma: an Epstein-Barr virus-associated tumor.
Jeng YM; Chen CL; Hsu HC
Am J Surg Pathol; 2001 Apr; 25(4):516-20. PubMed ID: 11257627
[TBL] [Abstract][Full Text] [Related]
14. Lymphoepithelioma-like cholangiocarcinoma (LELC) not associated with Epstein-Barr virus.
Szekely E
Am J Surg Pathol; 2001 Nov; 25(11):1464-6. PubMed ID: 11684969
[No Abstract] [Full Text] [Related]
15. Programmed death-ligand 1 is upregulated in intrahepatic lymphoepithelioma-like cholangiocarcinoma.
Wang L; Dong H; Ni S; Huang D; Tan C; Chang B; Sheng W
Oncotarget; 2016 Oct; 7(43):69749-69759. PubMed ID: 27626174
[TBL] [Abstract][Full Text] [Related]
16. Association of Plasma Epstein-Barr Virus DNA With Outcomes for Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma Receiving Anti-Programmed Cell Death 1 Immunotherapy.
Xu JY; Wei XL; Ren C; Zhang Y; Hu YF; Li JY; Chen JL; Wang YQ; Han F; Wang FH
JAMA Netw Open; 2022 Mar; 5(3):e220587. PubMed ID: 35230439
[TBL] [Abstract][Full Text] [Related]
17. Sintilimab treatment for chronic active Epstein-Barr virus infection and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in children.
Chen R; Lin Q; Zhu Y; Shen Y; Xu Q; Tang H; Cui N; Jiang L; Dai X; Chen W; Li X
Orphanet J Rare Dis; 2023 Sep; 18(1):297. PubMed ID: 37736751
[TBL] [Abstract][Full Text] [Related]
18. Characterization of PD-L1 and PD-1 Expression and CD8+ Tumor-infiltrating Lymphocyte in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
Larbcharoensub N; Mahaprom K; Jiarpinitnun C; Trachu N; Tubthong N; Pattaranutaporn P; Sirachainan E; Ngamphaiboon N
Am J Clin Oncol; 2018 Dec; 41(12):1204-1210. PubMed ID: 29672367
[TBL] [Abstract][Full Text] [Related]
19. Poor prognosis in Epstein-Barr virus-negative gastric cancer with lymphoid stroma is associated with immune phenotype.
Cho CJ; Kang HJ; Ryu YM; Park YS; Jeong HJ; Park YM; Lim H; Lee JH; Song HJ; Jung HY; Kim SY; Myung SJ
Gastric Cancer; 2018 Nov; 21(6):925-935. PubMed ID: 29627937
[TBL] [Abstract][Full Text] [Related]
20. Epstein-Barr virus infection-associated cholangiocarcinoma: a report of one case and the review of literature.
Zhang X; Wang N; Wei W; Li Y
Virol J; 2022 Aug; 19(1):133. PubMed ID: 35945590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
